2015
DOI: 10.1016/j.vaccine.2015.01.014
|View full text |Cite
|
Sign up to set email alerts
|

Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
17
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 17 publications
(21 citation statements)
references
References 47 publications
(79 reference statements)
4
17
0
Order By: Relevance
“…Other conserved Sp proteins, such as pneumococcal surface antigen A (PsaA), pneumolysin, pneumolysoid PdT, and histidine triad proteins have been used with potent adjuvants as subunit vaccines that protect mice against pneumonia. 24, 26, 27, 29, 33 Although these studies have not directly tested the role of memory Th17 cells in protection against pneumonia, these findings together with our results support the notion that Th17-inducing conserved Sp protein antigens might be vaccine candidates capable of conferring broad protection by inducing strong memory Th17 responses in the lungs.…”
Section: Resultssupporting
confidence: 68%
“…Other conserved Sp proteins, such as pneumococcal surface antigen A (PsaA), pneumolysin, pneumolysoid PdT, and histidine triad proteins have been used with potent adjuvants as subunit vaccines that protect mice against pneumonia. 24, 26, 27, 29, 33 Although these studies have not directly tested the role of memory Th17 cells in protection against pneumonia, these findings together with our results support the notion that Th17-inducing conserved Sp protein antigens might be vaccine candidates capable of conferring broad protection by inducing strong memory Th17 responses in the lungs.…”
Section: Resultssupporting
confidence: 68%
“…9 We have also shown that vaccination with monovalent and trivalent vaccines containing PhtD, PcpA or PlyD1 confer protection against pneumonia and sepsis in a mouse model. [17][18][19][20] Our work has also demonstrated a correlate of natural exposure-induced higher antibody levels to PhtD, PcpA and PlyD1 with protection against Spn-caused AOM in young children. 21,22 Sufficient promise for the potential of a trivalent PhtD, PcpA, and PlyD1 vaccine has emerged such that one is in human clinical trials for the prevention of pneumonia.…”
Section: Introductionsupporting
confidence: 57%
“…For example, recombinant Bacillus Calmette-Guerin (BCG) vaccine can decrease the infiltration of neutrophils within airways and reduce the viral loads in BALF in mice infected with respiratory syncytial virus (RSV) showing a potential to prevent pneumonia [157]. Trivalent pneumococcal protein recombinant vaccine vaccination results in a reduction in SP-induced lethality, enhanced early clearance of SP in lungs due to more rapid and thorough phagocytosis of SP by neutrophils, and correspondingly, a reduction in lung inflammation and tissue damage [158]. In addition, cathelin-related antimicrobial peptide appears to be protective in models of pneumonia [159].…”
Section: Neutrophils In Infectious Pneumoniamentioning
confidence: 99%